

Notes of the meeting of the South and West Devon Formulary Interface Group

Tuesday 16th July 2013, 2pm – 4pm, The Watermark, Erme Court, Leonards Road, Ivybridge PL21 0SZ

Present:	Chris Roome – Chair	NEW Devon CCG
	Phil Melluish – GP	South Devon CCG
	Keith Gillespie – GP, Chair PAJF	NEW Devon CCG
	Larissa Sullivan – Interface Pharmacist	NEW Devon CCG
	Sarah Marner – Interface Pharmacist	NEW Devon CCG
	Carol Webb – Joint Formularies Technician	NEW Devon CCG
	Margaret Hinchliffe	Lay member
	Jeremy Morris – Formulary Pharmacist	Plymouth Hospitals NHS Trust
	Andrew Prowse – Assistant Director of Pharmacy	Plymouth Hospitals NHS Trust
	Gareth Franklin – Clinical Guidance Manager	NEW Devon CCG
	Iain Roberts – Lead MO Pharmacist	South Devon CCG
	Elena Mercer – Formulary Pharmacist	South Devon NHS Trust
	Petrina Trueman – Joint Formularies Pharmacist	NEW Devon CCG
	Steve Cooke – Chief Pharmacist	Plymouth Community Healthcare
	Andrew Gunatilleke – Consultant, Chair SDNT DTC	South Devon NHS Trust

Apologies	Mike Finnegan – Consultant, Chair PHNT DTC	Plymouth Hospitals NHS Trust
	Paul Humphriss – Head of Medicines Management	South Devon NHS Trust
	Karen O’Brian – Community Pharmacist	Devon LPC
	Mark Stone – Community Pharmacist	Devon LPC
	Chris Sullivan – Prescribing Adviser	Devon Partnership Trust
	Amanda Gulbranson - Clinical Effectiveness Lead	Devon Partnership Trust
	Paul Hughes – Deputy Head of Prescribing	Kernow CCG

1 Welcome:

The Chair welcomed everyone.
Apologies as noted above.

2 Notes of last meeting 18th June 2013:

These were noted and agreed.

3 Action log:

- **Revised Osteoporosis pathway:** This was triggered by the concerns around the use of strontium. The formularies have been updated accordingly; a treatment pathway is being reviewed. It is hoped to bring a revised pathway to the September meeting.
There was discussion regarding the funding of GPs or District Nurses to administer denosumab in primary care. It is currently available for primary care use in the Western Locality, but it is thought that very little is being used.

Actions:

To bring a revised osteoporosis pathway to the next meeting

To look at the current prescribing data for denosumab across Devon

- **South Devon use of rivaroxaban in the treatment of DVT:** The haematologists in South Devon are happy with the amended guidance that came to the June meeting. There is a working group

set up to look at peripheral vascular disease and they will be looking at rivaroxaban.

A question was asked about PGD's and it was noted that these do not have to come to the formulary group to be agreed, they are appropriate to the individual issuing organisation.

Action: To finalise the wording of the rivaroxaban DVT guidance

4 Recent drug approvals (including NICE):

a) **South Devon Drugs & Therapeutics Committee:** No recent decisions

b) **Plymouth Hospitals Drugs & Therapeutics Committee:** Bevacizumab was discussed as it is now funded by the Cancer Drugs Fund as a cohort drug. There was discussion as to how the CDF cohort drugs will be included into the formulary.

Action: To decide how to represent CDF cohort drugs in the formulary

c) **Clinical Policy Committee:** See agenda item 5

d) **NICE update:** The appraisals and guidelines were detailed. There are three of note: TA288 and recommendation of dapagliflozin, the Derriford consultants are working on a revised pathway. It was agreed that the pathway being worked on by the Derriford clinicians be shared with the South Devon consultants for comment and a re-designed pathway to be brought to the next meeting

Action: revised pathway including dapagliflozin to be shared with South Devon consultants and brought to the next meeting

TA290 the recommendation of mirabegron, the NICE clinical guideline on urinary incontinence has been delayed so the place of mirabegron in therapy needs to be considered separately.

Action: the place of mirabegron in therapy to be brought to the next meeting

CG164 on familial breast cancer and the recommendation to treat with tamoxifen. There was discussion on how to assess suitable patients. This is being discussed at the next NICE Planning, Quality and Assurance Group (NPAG) meeting and may have some guidance on this.

e) **NICE guidance added to the formulary:** These were noted

5 COPD Pathway:

The decisions by the Clinical Policy Committee to approve for use indacaterol, glycopyrronium and aclidinium were reported together with the rationale behind the decisions. The drugs were discussed individually and their place in treatment was agreed.

It was agreed change formoterol and salmeterol to first-line drugs and to add indacaterol into the formulary as a second-line drug. It was also agreed to highlight that indacaterol is only licensed for treatment of COPD.

Glycopyrronium and aclidinium were discussed and it was agreed to add glycopyrronium as a first-line treatment, together with Tiotropium. It was agreed to add aclidinium into the formulary as a specialist initiated drug, and to add it to the pathway. This is also agreed by the consultants in both Trusts.

It was also suggested that the pathway be amended so that consideration is given to treating with an alternative first-line before moving on. It was agreed to amend this and to send it to the specialists for their opinion.

Action: To add into the formulary indacaterol, glycopyrronium and aclidinium and to amend the pathway to suggest considering a further first-line before moving on. To check with the specialists.

6 MHRA Drug Safety Update – June:

Hydroxyethyl starch intravenous infusion, suspension of licenses: these have been withdrawn from use in both Trusts.

Diclofenac, it was agreed to add this information. The Pain section of the formularies is currently being merged and this will be included in the final chapter.

Co-cyprindiol, this warning against additional contraception to be added.

Action: the warning against additional contraception with co-cyprindiol to be added to the formulary

7 Terms of Reference:

To be discussed at the next meeting

Elena Mercer left the meeting at this point

8 Formulary platform:

The proposed new formulary website and App were introduced to the committee. GF was thanked for the work that had gone into producing this. There was discussion on the promoting of the new website and App when completed and also the change of domain name that would have to be given.

Keith Gillespie, Sarah Marner and Iain Roberts left the meeting at this point

9 & Formulary merger work plan:

10 It was noted that antibiotics, pain and cardiovascular were underway. At least two of these should be coming to the next meeting. There was a reminder given that this is a merger of the formularies and not a full review, due to the time needed to complete this work.

The group were reminded of the agreement to change the day of the meeting to the 2nd Friday of every month. There was discussion on the length of time of the meeting to fit in the current length of the agendas. It was agreed to extend the time of the meeting to finish at 4:30pm

Next meeting: Friday 13th September 2013, 2pm – 4:30pm, The Watermark, Erme Court, Leonards Road, Ivybridge PL21 0SZ

South and West Devon Formulary Group – Action log			
Date	Action	Responsible	Completed
June 2013	To bring a revised osteoporosis pathway to the next meeting	GF	
July 2013	To look at the current prescribing data for denosumab across Devon	CW	Completed
July 2013	To finalise the wording of the rivaroxaban DVT guidance	SM/LS	Completed
July 2013	To decide how to represent CDF cohort drugs in the formulary	GF	Completed
July 2013	Revised pathway including dapagliflozin to be shared with South Devon consultants and brought to the next meeting	JM	Completed
July 2013	The place of mirabegron in therapy to be brought to the next meeting	GF	Completed
July 2013	To add into the formulary indacaterol, glycopyrronium and aclidinium and to amend the pathway to suggest considering a further first-line before moving on. To check with the specialists	CW/GF	Completed
July 2013	The warning against additional contraception with co-cyprindiol to be added to the formulary	CW	Completed